AgeX Therapeutics has drawn a $1.3 million tranche of financing pursuant to its unsecured loan facility from Juvenescence.
“Juvenescence is pleased to continue its commitment to AgeX through this additional drawdown under the loan facility,” said Gregory Bailey, MD, chairman of AgeX and CEO of Juvenescence. “Juvenescence remains committed to funding the future development plans of AgeX through further advancements under the loan facility or otherwise. Since Juvenescence’s initial investment in AgeX in June 2018, AgeX has been an important element in the Juvenescence mission and strategy. Juvenescence is also investing its time and personnel to support AgeX’s business development initiatives which have impressive potential.”_x000D_
In August, AgeX obtained a $2 million credit facility from Juvenescence to finance AgeX’s operations and advance its product development programs.
AgeX Therapeutics is focused on developing and commercializing innovative therapeutics for human aging.
